Compare GDL & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GDL | CING |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | United States |
| Employees | N/A | 13 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.4M | 93.1M |
| IPO Year | N/A | N/A |
| Metric | GDL | CING |
|---|---|---|
| Price | $8.32 | $8.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $37.00 |
| AVG Volume (30 Days) | 9.3K | ★ 519.2K |
| Earning Date | 01-01-0001 | 03-18-2026 |
| Dividend Yield | ★ 6.02% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.71 | $3.20 |
| 52 Week High | $8.67 | $11.89 |
| Indicator | GDL | CING |
|---|---|---|
| Relative Strength Index (RSI) | 34.17 | 53.20 |
| Support Level | $8.22 | $3.62 |
| Resistance Level | $8.45 | N/A |
| Average True Range (ATR) | 0.06 | 0.95 |
| MACD | -0.02 | 0.28 |
| Stochastic Oscillator | 0.00 | 36.20 |
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.